Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

NCT06498167 is registered in ClinicalTrials.gov with Universidade do Porto as lead sponsor.

NCT NCT06498167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06498167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)
Lead sponsor
Universidade do Porto
Phase
Observational
Overall status
Unknown status
Start date
July 1, 2024
Completion date
December 31, 2024
Enrollment
150 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adverse drug event, adverse drug reaction, drug side effect, drug use, inflammatory disease, safety issues